Using Big Data and Predictive Analytics to Determine Patient Risk in Oncology

August 20, 2019 Andrew Hertler, MD, FACP

Dr. Andrew Hertler, Chief Medical Officer at New Century Health, and other experts describe the potential of big data and predictive analytics to improve clinical risk stratification for cancer patients. To read the full report from ASCO, please click here

--

Big data and predictive analytics have immense potential to improve risk stratification, particularly in data-rich fields like oncology. This paper reviews the literature published on use cases and challenges in applying predictive analytics to improve risk stratification in oncology. We characterized evidence-based use cases of predictive analytics in oncology into three distinct fields: (1) population health management, (2) radiomics, and (3) pathology. We then highlight promising future use cases of predictive analytics in clinical decision support and genomic risk stratification. We conclude by describing challenges in the future applications of big data in oncology, namely (1) difficulties in acquisition of comprehensive data and endpoints, (2) the lack of prospective validation of predictive tools, and (3) the risk of automating bias in observational datasets. If such challenges can be overcome, computational techniques for clinical risk stratification will in short order improve clinical risk stratification for patients with cancer. 

Click here to download the full article

 

 

About the Author

Andrew Hertler, MD, FACP

As the chief medical officer of Evolent, Dr. Andrew Hertler is responsible for the advancement of the company's clinical quality and value-based strategy, utilization management policies and clinical thought leadership initiatives. A practicing board-certified oncologist for 30 years, he is a nationally recognized leader in oncology clinical practice. Dr. Hertler has volunteered on a number of American Society of Clinical Oncology (ASCO) committees, including the Clinical Practice, Quality of Care and Payment Reform Committees, as well as the Quality Oncology Practice Initiative Certification Program Oversight Council.

Follow on Linkedin More Content by Andrew Hertler, MD, FACP
Previous Article
Putting the CAR-T Before the Horse? Understanding CMS’ Recent Cancer Therapy Decisions
Putting the CAR-T Before the Horse? Understanding CMS’ Recent Cancer Therapy Decisions

Dr. Hertler, CMO at New Century Health, shares his thoughts and perspectives on the future of CAR T-cell th...

Next Article
Cancer Care Costs Everyone Too Much. Here's How We Fix It.
Cancer Care Costs Everyone Too Much. Here's How We Fix It.

Dr. Andrew Hertler, Chief Medical Officer at New Century Health, demonstrates how clinical pathways improve...

×

First Name
Last Name
Company Name
Thank you!
Error - something went wrong!